Leica Biosystems gains FDA clearance for AI quality-control software in cancer pathology

Leica Biosystems' portfolio expansion addresses a critical pain point in diagnostic pathology: the shift from glass slide microscopy to digital imaging has introduced new quality challenges that slow down case processing. Artifacts introduced during tissue preparation, staining, coverslipping, and scanning—such as air bubbles and out-of-focus regions—have traditionally required manual inspection and often rescanning, both of which delay diagnosis. By embedding AI quality control directly into the scanning workflow rather than as a downstream step, Aperio iQC DX software catches these defects when they are easiest and cheapest to address, reducing rework and accelerating case throughput.

The 24% improvement in artifact detection over human review and 69% reduction in manual review time suggest the AI model has learned patterns histotechnicians commonly miss. This efficiency gain is particularly valuable at a time when diagnostic complexity is rising alongside staffing shortages and growing case volumes. By automating routine quality checks, the software frees skilled staff to focus on higher-value diagnostic tasks, helping laboratories maintain both speed and diagnostic confidence. The company's position within Danaher's ecosystem—which supports nearly 2 million cancer tests globally each week—gives it scale to refine these models and integrate them across a full biopsy-to-diagnosis workflow, potentially setting a new standard for digital pathology quality.